Pfizer buys back into obesity drug chase with $4.9B Metsera deal

The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.

AbbVie stakes $335M on a startup’s RNAi drugs

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

March 12, 2026

NEMA, stakeholders review 2025 disasters, boost preparedness in Kaduna – EnviroNews

March 12, 2026

Source link

Pfizer buys back into obesity drug chase with $4.9B Metsera deal

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

NEMA, stakeholders review 2025 disasters, boost preparedness in Kaduna – EnviroNews

A Last Chance for Crypto Traders Before the 2026 Crackdown?

Moove Sets Sights on Becoming Africa’s Next Unicorn with $300 Million Funding Round, Eyeing $2 Billion Valuation

Moove Sets Sights on Becoming Africa's Next Unicorn with $300 Million Funding Round, Eyeing $2 Billion Valuation

Leave a Reply Cancel reply

RECOMMENDED NEWS

UK Government seeks input on new CO2 transportation options

The Total, Final Obliteration Of Free Speech In 2024

BRICS Will Discuss Use of Local Currencies at August Summit

performance artist Puppies Puppies exhibits herself in a glass box for four months

POPULAR NEWS

Mahama attends Liberia’s 178th independence anniversary

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

Pfizer buys back into obesity drug chase with $4.9B Metsera deal

Related posts

A Last Chance for Crypto Traders Before the 2026 Crackdown?

Moove Sets Sights on Becoming Africa’s Next Unicorn with $300 Million Funding Round, Eyeing $2 Billion Valuation

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS